Stay updated on Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial page.

Latest updates to the Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedLocations section updated to include Florida as a study site under Locations, with the dedicated Florida Locations subsection removed; the HHS Vulnerability Disclosure link has also been removed.SummaryDifference0.2%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe Publications note was updated to say PubMed auto-fills publications; the older wording was removed, and a new page revision number v3.3.2 was added.SummaryDifference0.1%

- Check52 days agoChange DetectedRemoved a banner about government funding and operating status. The core study details and contacts remain unchanged.SummaryDifference0.3%

- Check66 days agoChange DetectedNo substantive changes were observed in core study information (title, conditions, eligibility criteria, endpoints, or interventions); observed differences appear limited to formatting and minor text edits. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check95 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 tag removed. Core content impacted by the new status information.SummaryDifference3%

- Check102 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial page.